Literature DB >> 10695718

Pathogenesis of Guillain-Barré syndrome.

R A Hughes1, R D Hadden, N A Gregson, K J Smith.   

Abstract

Recent neurophysiological and pathological studies have led to a reclassification of the diseases that underlie Guillain-Barré syndrome (GBS) into acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor and sensory axonal neuropathy (AMSAN) and acute motor axonal neuropathy (AMAN). The Fisher syndrome of ophthalmoplegia, ataxia and areflexia is the most striking of several related conditions. Significant antecedent events include Campylobacter jejuni (4-66%), cytomegalovirus (5-15%), Epstein-Barr virus (2-10%), and Mycoplasma pneumoniae (1-5%) infections. These infections are not uniquely associated with any clinical subtype but severe axonal degeneration is more common following C. jejuni and severe sensory impairment following cytomegalovirus. Strong evidence supports an important role for antibodies to gangliosides in pathogenesis. In particular antibodies to ganglioside GM1 are present in 14-50% of patients with GBS, and are more common in cases with severe axonal degeneration associated with any subtype. Antibodies to ganglioside GQ1b are very closely associated with Fisher syndrome, its formes frustes and related syndromes. Ganglioside-like epitopes exist in the bacterial wall of C. jejuni. Infection by this and other organisms triggers an antibody response in patients with GBS but not in those with uncomplicated enteritis. The development of GBS is likely to be a consequence of special properties of the infecting organism, since some strains such as Penner 0:19 and 0:41 are particularly associated with GBS but not with enteritis. It is also likely to be a consequence of the immunogenetic background of the patient since few patients develop GBS after infection even with one of these strains. Attempts to match the subtypes of GBS to the fine specificity of anti-ganglioside antibodies and to functional effects in experimental models continue but have not yet fully explained the pathogenesis. T cells are also involved in the pathogenesis of most or perhaps all forms of GBS. T cell responses to any of three myelin proteins, P2, PO and PMP22, are sufficient to induce experimental autoimmune neuritis. Activated T cells are present in the circulation in the acute stage, up-regulate matrix metalloproteinases, cross the blood-nerve barrier and encounter their cognate antigens. Identification of the specificity of these T cell responses is still at a preliminary stage. The invasion of intact myelin sheaths by activated macrophages is difficult to explain according to a purely T cell mediated mechanism. The different patterns of GBS are probably due to the diverse interplay between antibodies and T cells of differing specificities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695718     DOI: 10.1016/s0165-5728(99)00195-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  81 in total

1.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

2.  Neurologic symptoms associated with raising poultry and swine among participants in the Agricultural Health Study.

Authors:  Meghan F Davis; Freya Kamel; Jane A Hoppin; Michael C R Alavanja; Laura Beane Freeman; Gregory C Gray; Kenrad Nelson; Ellen Silbergeld
Journal:  J Occup Environ Med       Date:  2011-02       Impact factor: 2.162

3.  Detection on surfaces and in Caco-2 cells of Campylobacter jejuni cells transformed with new gfp, yfp, and cfp marker plasmids.

Authors:  W G Miller; A H Bates; S T Horn; M T Brandl; M R Wachtel; R E Mandrell
Journal:  Appl Environ Microbiol       Date:  2000-12       Impact factor: 4.792

Review 4.  Immunotherapy of inflammatory demyelinating diseases of the central nervous system.

Authors:  J J Bright; S Sriram
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 5.  Therapy of immune neuropathies with intravenous immunoglobulins.

Authors:  Ralf Gold; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Acute polyradiculoneuritis in Sarajevo during the war.

Authors:  Jasminka Delilović-Vranić; Sajma Dautović-Krkić
Journal:  Bosn J Basic Med Sci       Date:  2006-02       Impact factor: 3.363

7.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

8.  Enhanced, sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages.

Authors:  Astrid P Heikema; Roman I Koning; Sharon Duarte dos Santos Rico; Hans Rempel; Bart C Jacobs; Hubert P Endtz; Willem J B van Wamel; Janneke N Samsom
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

9.  Silencing of miR155 promotes the production of inflammatory mediators in Guillain-Barré syndrome in vitro.

Authors:  Yu-Zhong Wang; Xun-Gang Feng; Qi-Guang Shi; Yan-Lei Hao; Yan Yang; Ai-Mei Zhang; Qing-Xia Kong
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

10.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.